Clinical Trials Sponsored by Kiniksa Pharmaceuticals (UK), Ltd.

Total 17 results

Kiniksa Pharmaceuticals (UK), Ltd.

Completed

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis (RHAPSODY)

Recurrent Pericarditis

United States, Israel, Australia, Italy
Kiniksa Pharmaceuticals (UK), Ltd.

Recruiting

REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients (RESONANCE)

Recurrent Pericarditis

United States
Kiniksa Pharmaceuticals (UK), Ltd.

Completed

A Pilot Study of KPL-914 in Recurrent Pericarditis

Recurrent Pericarditis

United States
Kiniksa Pharmaceuticals, Ltd.

Completed

KPL-301 for Subjects With Giant Cell Arteritis

Giant Cell Arteritis

United States, Belgium, Croatia, Germany, Italy, Poland, Serbia, United Kingdom, Australia, Estonia, Ireland, Netherlands, New Zealand, Slovenia, Spain
Kiniksa Pharmaceuticals, Ltd.

Completed

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

COVID

United States, Brazil, South Africa, Chile, Peru
Kiniksa Pharmaceuticals, Ltd.

Active, not recruiting

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Arthritis, Rheumatoid

United States, Poland, Hungary, Georgia, Czechia, South Africa, Bulgaria
Kiniksa Pharmaceuticals, Ltd.

Completed

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Prurigo Nodularis | Pruritis

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Poland, Taiwan, United Kingdom
Kiniksa Pharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Plaque Psoriasis | Chronic Idiopathic Urticaria | Lichen Planus | Lichen Simplex Chronicus | Chronic Idiopathic Pruritus

United States
Kiniksa Pharmaceuticals, Ltd.

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

Healthy Volunteers

Australia, United States
Virginia Commonwealth University
Kiniksa Pharmaceuticals, Ltd.

Completed

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

COVID-19 | Pneumonia | Sars-CoV2

United States
The Cleveland Clinic
Kiniksa Pharmaceuticals, Ltd.

Completed

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Pneumonia | SARS-CoV 2 | COVID 19

United States
Kristin Hudock
Kiniksa Pharmaceuticals, Ltd.

Unknown

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation

Pneumonia | SARS-CoV 2 | COVID 19

United States
Clinuvel (UK) Ltd.

Completed

DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers

Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers

United Kingdom
Clinuvel (UK) Ltd.

Completed

Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)

Variegate Porphyria

Netherlands
Centessa Pharmaceuticals (UK) Limited
LockBody Therapeutics Ltd

Recruiting

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

United States, France
University College, London
MODEPHARMA Limited; PARKINSONS UK; PRIMENT; SEALED ENVELOPE; Wasdell Packaging Ltd; Custom Pharmaceuticals Limited

Active, not recruiting

Trial of Ondansetron as a Parkinson's HAllucinations Treatment (TOP HAT)

Dementia With Lewy Bodies | Parkinson's Hallucinations

United Kingdom
The George Institute for Global Health, China
Takeda; Medical Research Council; Department for International Development, United... and other collaborators

Completed

The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT3)

Cardiovascular Diseases | Stroke | Central Nervous System Diseases | Hypertension | Diabetes | Hemorrhage | Intracranial Hemorrhages | Cerebral Hemorrhage | Anticoagulant-induced Bleeding | Cerebral Vascular Disorder | Brain Disorder

China

Clinical Trials Sponsored by Kiniksa Pharmaceuticals (UK), Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations